Daclatasvir (trade name: Daklinza) is a medication used in combination with other medications to treat hepatitis C (HCV). Daclatasvir stops HCV viral RNA replication and protein translation by directly inhibiting HCV protein NS5A which is critical for HCV viral transcription and translation. Daclatasvir has been approved by the U.S Food and Drug Administration on June 24, 2015.
Product Name: Daclatasvir
CAS Number: 1009119-64-5
Molecular Weight:  738.885
Molecular Formula:  C40H50N8O6
Purity (HPLC): ≥99%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.